mAbxience Announces Licensing Agreement with Intas Pharmaceuticals Ltd. for Etanercept Biosimilar Targeting Autoimmune Diseases in more than 150 Countries, including Europe and the United States of AmericaMiguel Martínez-Cava2023-12-20T10:49:24+01:00December 20, 2023|Press releases|
mAbxience and Abdi İbrahim Announce Landmark Technology Transfer Agreement, Advancing Biotechnology in TürkiyeMiguel Martínez-Cava2023-11-20T08:43:23+01:00November 20, 2023|Press releases|
mAbxience and MS Pharma Sign Partnership for Denosumab Biosimilar in Select MEA CountriesMiguel Martínez-Cava2023-11-13T07:53:41+01:00November 13, 2023|Press releases|
From lab to market: mAbxience’s approach to biopharmaceutical developmentadriana.polo2024-12-02T12:04:35+01:00December 2, 2024|News|
Biosimilar production: challenges and strategiesadriana.polo2024-11-19T11:06:10+01:00November 19, 2024|News|
The role of CDMOs in global healthcare advancementsadriana.polo2024-11-20T10:15:33+01:00November 8, 2024|News|
